Unknown PHASE3 INTERVENTIONAL 2-arm NCT01270490

Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia

A Multicentre, Prospective, Randomized Open-label Pilot Study to Assess the Feasibility and Preliminary Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia

Sponsor: BioMérieux

Conditions Candidemia

Interventions Interferon-gamma, Recombinant

Updated 7 times since 2017 Last updated: Feb 13, 2012 Started: Jan 31, 2011 Primary completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01270490, this PHASE3 trial focuses on Candidemia and remains ongoing. Sponsored by BioMérieux, it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Mar 2022 — Jul 2024 [monthly]

Unknown Status PHASE3
Jan 2021 — Mar 2022 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE3
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE3

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioMérieux
Radboud University Medical Center

Data source: Radboud University Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nijmegen, Netherlands